- Sarepta turns to Michael Severino as CEO, looking to move past recent turmoilSarepta Therapeutics has found its new CEO as it seeks to recover from a calamitous past year. Michael Severino will replace the company’s longtime leader Doug Ingram on Tuesday. Severino joins fro…Endpoints · 1d ago↗ source
- Argenx deepens immuno expertise with $2.2B Forte Biosciences buyThe star of the takeover is Forte Biosciences' investigational antibody therapy, FB102, which has shown early potential in vitiligo and celiac disease.BioSpace · 1d ago↗ source
- [Podcast] From Protocol to Patient: Inside Clinical Supply with Almac Clinical ServicesThis podcast explores how clinical trial supplies move from early planning to global delivery, ensuring investigational medicines reach patients safely and on time.